ADAXION Therapeutics

📍 San Diego, United States🗓 Founded 2022👥 23 employees💰 Last funded Jan 2021
Biotechnology Research🌐 adaxiontx.com
Website LinkedIn
ADAXION Therapeutics is transforming the future of biotherapeutics by tackling one of the biggest challenges in drug development: immunogenicity. Based in San Diego, the company is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx platform. This technology is designed to deimmunize protein therapeutics—preventing the formation of anti-drug antibodies (ADAs) that can compromise efficacy and trigger harmful immune responses. The ADAx platform uses proprietary CD22 ligands to selectively eliminate therapeutic-specific B cells while preserving the full functionality of the biologic and maintaining overall immune competence. This drug-specific approach enables the development of first- and best-in-class biologics that would otherwise be limited by immunogenicity. With a growing pipeline and a focus on addressing unmet medical needs, ADAXION is unlocking the full potential of biologics to enhance therapeutic performance and expand their clinical impact.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in ADAXION Therapeutics?
ADAXION Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did ADAXION Therapeutics last raise funding?
The most recent investment in ADAXION Therapeutics recorded on gritt.io was in January 2021.
When was ADAXION Therapeutics founded?
ADAXION Therapeutics was founded in 2022.
What industry is ADAXION Therapeutics in?
ADAXION Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ADAXION Therapeutics based?
ADAXION Therapeutics is headquartered in San Diego, United States.